loading . . . Efficacy and safety of horse-assisted therapy in neurological and developmental disorders: a systematic review - Discover Medicine Horse-assisted therapy (HAT) is increasingly used in neurological and developmental disorders despite substantial heterogeneity in intervention protocols, outcome measures, and methodological quality. This growing clinical interest, together with inconsistent evidence regarding efficacy and safety across conditions, highlights the need for a critical synthesis of the current literature. We conducted a systematic review to evaluate the efficacy and safety of HAT in multiple sclerosis (MS), cerebral palsy (CP), Down syndrome (DS), and autism spectrum disorder (ASD). MEDLINE, EMBASE, and the Cochrane Library were searched for randomized controlled trials (RCTs) and systematic reviews (SRs) published between January 2017 and October 2024; the protocol was prospectively registered in the Open Science Framework (OSF, https://bit.ly/4u07oNo ). Reviews including non-randomized studies, non-equine interventions, or mixed animal-assisted therapies were excluded. Two reviewers independently screened records, extracted data, and assessed study quality using RoB-2 (RCTs) and AMSTAR-2 (SRs). Due to heterogeneity in populations, interventions, and outcomes, results were synthesized narratively. No external funding was received. Eight studies met the inclusion criteria (5 RCTs, 3 SRs; 452 children with CP, 103 participants with MS, 34 children with DS, and 240 children with ASD) addressing CP, MS, DS, and ASD. Across studies, HAT was associated with modest improvements in gross motor function and postural control (GMFM, PBS), walking performance (6MWT, T25FW), and selected social and communication outcomes. Evidence for DS was limited. Safety data were scarce: one trial reported no serious adverse events, while another documented adverse events without clear attribution to the intervention. Overall, methodological quality varied, with frequent limitations including small sample sizes, heterogeneous protocols, and limited blinding. In conclusion, HAT may offer domain-specific benefits in selected populations, but current evidence remains insufficient for routine clinical implementation; larger, preregistered, methodologically rigorous RCTs with standardized protocols and systematic safety reporting are needed. https://bit.ly/4tw6loE